Go Pro

Crescent Biopharma (CBIO) Earnings Date, Estimates & Call Transcripts

Crescent Biopharma logo
$17.27 +0.43 (+2.54%)
As of 03:47 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Crescent Biopharma Earnings Summary

Crescent Biopharma announced Q2 2026 earnings on July 30, 2026, reporting an EPS of -$0.74, which missed analysts' consensus estimates of -$0.74 by $0.00. With a trailing EPS of -$6.72, Crescent Biopharma's earnings are expected to decrease next year, from ($2.91) to ($3.13) per share.

Q2 2026 Earnings Resources

Latest Q2 2026
Earnings Date
Jul. 30Estimated
Consensus EPS
(Jul. 30)
-$0.74
Actual EPS
(Jul. 30)
-$0.74 Missed By -$0.00
Get Crescent Biopharma Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Crescent Biopharma and other key companies, straight to your inbox.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Estimated and Actual Earnings Data

CBIO Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

CBIO Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Crescent Biopharma Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20262-$0.91-$0.76-$0.84
Q2 20262-$0.96-$0.79-$0.88
Q3 20262-$0.85-$0.64-$0.75
Q4 20262-$0.86-$0.60-$0.73
FY 2026 8 -$3.58 -$2.79 -$3.19
Q1 20271-$0.99-$0.99-$0.99
Q2 20271-$1.08-$1.08-$1.08
Q3 20271-$1.16-$1.16-$1.16
Q4 20271-$1.37-$1.37-$1.37

Crescent Biopharma Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
7/30/2026Q2 2026-$0.7357-$0.74 -$0.0043-$0.74$0.36M-
4/29/2026Q1 2026-$0.85-$0.70+$0.15-$0.70$0.36M$1.04M
2/26/2026Q4 2025-$2.22-$4.01 -$1.79-$4.01-$10.84M
11/6/2025Q3 2025-$1.01-$1.27 -$0.26-$1.27--

Crescent Biopharma Earnings - Frequently Asked Questions

Crescent Biopharma (NASDAQ:CBIO) last announced its quarterly earning data on Thursday, July 30, 2026. Learn more on CBIO's earnings history.

In the previous quarter, Crescent Biopharma (NASDAQ:CBIO) missed the analysts' consensus estimate of ($0.74) by $0.00 with a reported earnings per share (EPS) of ($0.74). Learn more on analysts' earnings estimate vs. CBIO's actual earnings.

Crescent Biopharma (NASDAQ:CBIO) has a recorded annual revenue of $10.84 million.

Crescent Biopharma (NASDAQ:CBIO) has a recorded net income of -$153.94 million. CBIO has generated -$6.72 earnings per share over the last four quarters.

Crescent Biopharma's earnings are expected to decrease from ($2.91) per share to ($3.13) per share in the next year.


Earnings data for NASDAQ:CBIO is sourced from Fiscal.ai, with the most recent quarter reported on 7/30/2026. New results are added as companies report their earnings.
From Our Partners